# Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia

> **NCT03230864** · PHASE3 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 119 (actual)

## Conditions studied

- Treatment-resistant Schizophrenia

## Interventions

- **DRUG:** Lu AF35700
- **DRUG:** Risperidone
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT03230864
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-20
- **Primary completion:** 2018-12-23
- **Final completion:** 2019-02-05
- **Target enrollment:** 119 (ACTUAL)
- **Why stopped:** New data; the study was terminated based on new efficacy data from another study
- **Last updated:** 2020-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230864, "Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03230864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*